The president made a wide variety of claims Wednesday night. Some were true, some were misleading, and others were false.

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

As physicians across specialties encounter increasing patient interest in GLP-1 receptor agonists, it is important for them ...

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...

Biotech innovator accelerated growth in 2025, doubled headcount, and expanded operations in the US The Cradle platform provides AI protein design tools trained on unique customer data and tailored for ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...